Clincial Study Patient Recruitment and Site Engagement

Gastroesophageal Cancer

Stark Raving Branding and Digital Marketing

Mountaineer-02: A Clincial Study for Her2+ Gastroesophageal Cancer



IndicationHER2+ Gastric Cancer


MaterialsStudy Branding

 Patient Outreach

 Patient Education

 Site Staff Materials

 Referring Physician

 Patient Retention

A campaign to support a randomized, double-blind, placebo-controlled, active comparator Phase 2/3 study of an investigational drug in combination with trastuzumab, ramucirumab, and paclitaxel in subjects with previously treated, locally-advanced unresectable or metastatic HER2+ gastric or gastroesophageal junction adenocarcinoma (GEC).

This study was conducted to see if tucatinib in combination with trastuzumab, ramucirumab and paclitaxel was more effective than ramucirumab and paclitaxel to treat HER2-positive (HER2+) gastroesophageal cancer. This study also evaluated the side effects of this combination of drugs. Study treatment were given in 28-day cycles.

Stark Raving Branding and Digital Marketing

Let's talk about your next project
To discuss an upcoming project or to learn more about our services, please contact us.

Be sure you complete all fields. Thank you!